Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era

Saved in:
Bibliographic Details
Published in:Rare Cancers and Therapy
Format: Online Article RSS Article
Published: 2026
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867301677553418242
collection WordPress RSS
FRELIP Feed Integration
container_title Rare Cancers and Therapy
description
discipline_display Oncology
discipline_facet Oncology
format Online Article
RSS Article
genre Journal Article
id rss_article:61385
institution FRELIP
journal_source_facet Rare Cancers and Therapy
publishDate 2026
publishDateSort 2026
record_format rss_article
spellingShingle Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
Oncology
General
Oncology
sub_discipline_display General
sub_discipline_facet General
subject_display Oncology
General
Oncology
Oncology
General
Oncology
subject_facet Oncology
General
Oncology
title Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_auth Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_full Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_fullStr Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_full_unstemmed Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_short Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
title_sort repurposing resmetirom to suppress masld/mash-hcc in the dysmetabolic era
topic Oncology
General
Oncology
url https://link.springer.com/article/10.1007/s40487-026-00442-x